Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

EyeMax™ IOL: a new approach to macular disease

Poster Details

First Author: F.Badala ITALY

Co Author(s):                        

Abstract Details


To determine the safety and efficacy of a new intraocular implant, iolAMD EyeMax™, (London Eye Hospital Pharma, London, UK) in cataract patients with dry and stable wet age-related macular degeneration.


Micro Chirurgia Oculare - Milano. Private Practice


A prospective case series of 52 eyes (37 patients) who underwent standard phacoemulsification with Eyemax implantation and have at least 4 months follow up. Outcomes were distant and near visual acuity, intra- and postoperative complications.


Visual Acuity improved significantly in all patients, for both distance (17 ETDRS mean letters gain) and near (24 ETDRS mean letters gain). All patients were left intentionally hyperopic to get additional magnification from spectacle correction. No intra-op or post-op complications were observed.


The Eyemax IOL shows promising results in improving distance and near vision in eyes with cataracts and macular degeneration. Near visual acuity seems to benefit the most. Further studies are needed to confirm results.

Financial Disclosure:


Back to Poster listing